SCHEMBL1018460

SCHEMBL1018460

COc1ccc(Cc2nsc(NCC(C)N)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP2D6 P10635 1/20 0.39
ATM Q13315 1/20 0.39
HTR6 P50406 1/20 0.38
LTA4H P09960 1/20 0.38
HPGD P15428 1/20 0.37
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020400 0.88 SLC6A4 (0.41) SLC6A4LMNAMAPTNPC1RAB9A
SCHEMBL1021254 0.88 LMNA (0.40) SLC6A4LMNAMAPTNPC1RAB9A
SCHEMBL1021153 0.86 LMNA (0.39) SLC6A4LMNAMAPTNPC1RAB9A
SCHEMBL1021097 0.86 TAAR1 (0.49) NPC1ALDH1A1HTR6LTA4HHPGD
SCHEMBL1021104 0.86 GBA1 (0.38) LMNAMAPTNPC1RAB9AALDH1A1
SCHEMBL1019826 0.85 ALDH1A1 (0.37) ALDH1A1HTR6TLR8TLR7
SCHEMBL1020893 0.85 SLC6A2 (0.41) MAPTNPC1RAB9AALDH1A1HTR6
SCHEMBL1023581 0.84 SLC6A2 (0.38) SLC6A4LMNAALDH1A1HTR6
SCHEMBL1019458 0.82 MAPT (0.43) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1021363 0.81 MAPT (0.39) SLC6A4LMNAMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP SLC6A4 3714/4885LMNA 1913/4885MAPT 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.